[go: up one dir, main page]

MA27854A1 - Traitement au moyen d'anticorps anti-vegf - Google Patents

Traitement au moyen d'anticorps anti-vegf

Info

Publication number
MA27854A1
MA27854A1 MA28652A MA28652A MA27854A1 MA 27854 A1 MA27854 A1 MA 27854A1 MA 28652 A MA28652 A MA 28652A MA 28652 A MA28652 A MA 28652A MA 27854 A1 MA27854 A1 MA 27854A1
Authority
MA
Morocco
Prior art keywords
treatment
vegf antibodies
vegf
relates
ami
Prior art date
Application number
MA28652A
Other languages
English (en)
Inventor
Fyfe Gwendolyn
Holmgren Eric
D Mass Robert
Novotny William
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27854(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA27854A1 publication Critical patent/MA27854A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne en général le traitement des maladies et des états pathologiques avec des anticorps anti-VEGF. Plus spécifiquement, l'invention concerne le traitement des patients humains susceptibles ou diagnostiqués par le cancer en utilisant un anticorps ami-VEGF, de préférence en association avec un ou plusieurs agents thérapeutiques antitumoraux supplémentaires.
MA28652A 2003-05-30 2005-12-12 Traitement au moyen d'anticorps anti-vegf MA27854A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47448003P 2003-05-30 2003-05-30

Publications (1)

Publication Number Publication Date
MA27854A1 true MA27854A1 (fr) 2006-04-03

Family

ID=33551495

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28652A MA27854A1 (fr) 2003-05-30 2005-12-12 Traitement au moyen d'anticorps anti-vegf

Country Status (23)

Country Link
US (41) US20050186208A1 (fr)
EP (4) EP2251355A1 (fr)
JP (8) JP2007525466A (fr)
KR (11) KR20170073698A (fr)
CN (2) CN1829741A (fr)
AU (2) AU2004251168A1 (fr)
BR (1) BRPI0411200A (fr)
CA (1) CA2526085A1 (fr)
CO (1) CO5640150A2 (fr)
CR (1) CR8108A (fr)
EC (1) ECSP056187A (fr)
IL (4) IL171833A (fr)
MA (1) MA27854A1 (fr)
ME (1) ME00425B (fr)
MX (1) MXPA05012723A (fr)
NO (1) NO20056236L (fr)
NZ (1) NZ621449A (fr)
RS (5) RS20050885A (fr)
RU (4) RU2005136988A (fr)
TN (1) TNSN05300A1 (fr)
UA (1) UA101945C2 (fr)
WO (1) WO2005000900A1 (fr)
ZA (1) ZA200509059B (fr)

Families Citing this family (264)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2003002609A2 (fr) * 2001-06-28 2003-01-09 Domantis Limited Ligand
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
BR122012021252B8 (pt) 2002-09-06 2021-05-25 Cerulean Pharma Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
AU2003290330A1 (en) * 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
RS20050885A (sr) * 2003-05-30 2008-04-04 Genentech Lečenje sa anti-vegf antitelima
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA2598239C (fr) 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Formes nanoparticulaires de taxanes et proteines porteuses a utiliser dans la chimiotherapie combinee
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
EP3050963B1 (fr) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble
ES2384267T3 (es) * 2005-07-21 2012-07-03 Nuvo Research Ag Soluciones de clorito estabilizadas en combinación con fluoropirimidinas para el tratamiento del cáncer
WO2007015556A1 (fr) 2005-08-01 2007-02-08 Canon Kabushiki Kaisha Dispositif de detection d'une substance cible, procede de detection d'une substance cible l'utilisant, et appareil de detection et ensemble destine a cet effet
JP4878238B2 (ja) * 2005-08-01 2012-02-15 キヤノン株式会社 標的物質検出用の素子及びそれを用いた標的物質の検出方法、並びにそのための検出装置及びキット
RU2414924C2 (ru) * 2005-08-12 2011-03-27 Ридженерон Фармасьютикалз, Инк. Способы лечения заболеваний антагонистами vegf
AU2006284657B2 (en) 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
JP2009519011A (ja) * 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
MX2008012279A (es) * 2006-03-29 2008-10-08 Genentech Inc Diagnostico y tratamientos para tumores.
CA2647846C (fr) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methodes de controle de la pharmacocinetique sanguine des anticorps
MY157366A (en) * 2006-04-10 2016-05-31 Fusion Antibodies Ltd Therapies and compositions comprising cathepsin s antibodies
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
WO2007137981A1 (fr) * 2006-05-25 2007-12-06 Novartis Ag Inhibiteurs de tyrosine kinases
CA2654000A1 (fr) * 2006-06-06 2008-05-22 Genentech, Inc. Anticorps anti-dll4 et leurs procedes d'utilisation
CA2654304A1 (fr) * 2006-06-06 2007-12-13 Genentech, Inc. Compositions et procedes destines a moduler le developpement vasculaire
EP2040751A2 (fr) * 2006-06-15 2009-04-01 Biogen Idec MA Inc. Thérapie combinée utilisant des molécules de liaison au récepteur de la lymphotoxine bêta associées avec d'autres agents
RU2432155C3 (ru) 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. Составы антагониста vegf, подходящие для интравитреального введения
WO2008022746A1 (fr) * 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Thérapie tumorale avec anticorps anti-vegf
US10118970B2 (en) * 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
US20100112077A1 (en) * 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
DK2117520T3 (en) 2006-12-14 2019-01-07 Abraxis Bioscience Llc BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN
AU2014201795B2 (en) * 2006-12-19 2016-05-19 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
CN103143017A (zh) * 2006-12-19 2013-06-12 基因技术公司 用于辅助和新辅助疗法以及早期肿瘤的治疗的vegf特异性拮抗剂
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
WO2008091222A1 (fr) * 2007-01-26 2008-07-31 Bioinvent International Ab Inhibiteurs de la signalisation dll4 et utilisations associees
AU2008210521A1 (en) * 2007-02-01 2008-08-07 Genentech, Inc. Combination therapy with angiogenesis inhibitors
EA200901301A1 (ru) 2007-06-06 2010-06-30 Домантис Лимитед Полипептиды, вариабельные домены антител и антагонисты
CL2008002782A1 (es) * 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
ES2653855T3 (es) * 2007-09-26 2018-02-09 Indiana University Research And Technology Corporation Derivado de la benzoquinona e3330 en combinación con agentes quimioterapéuticos para el tratamiento del cáncer y la angiogénesis
US11331294B2 (en) 2007-09-26 2022-05-17 Indiana University Research And Technology Corporation Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
WO2009055343A2 (fr) * 2007-10-22 2009-04-30 Schering Corporation Anticorps anti-vegf entièrement humains et leurs procédés d'utilisation
PE20090983A1 (es) * 2007-11-09 2009-08-13 Genentech Inc Composiciones y metodos de uso de la quinasa-1 similar al receptor de la activina
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
BRPI0821417A2 (pt) * 2007-12-26 2015-06-16 Biotest Ag Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo
US8580755B2 (en) * 2008-02-19 2013-11-12 University Of Rochester Methods and compositions for treating inflammatory conditions
WO2009149150A2 (fr) * 2008-06-03 2009-12-10 Alza Corporation Composition comprenant de la doxorubicine piégée par liposomes et procédés d'administration
AU2009264566B2 (en) 2008-06-25 2014-05-08 Novartis Ag Solubility optimization of immunobinders
KR102095257B1 (ko) 2008-06-25 2020-04-01 노바르티스 아게 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
ES2644723T3 (es) 2008-07-23 2017-11-30 F. Hoffmann-La Roche Ag Identificación de sujetos susceptibles de tratamiento antiangiogénico
JP2011528798A (ja) * 2008-07-23 2011-11-24 エフ．ホフマン−ラ ロシュ アーゲー 抗血管形成療法のモニター
WO2010025414A2 (fr) * 2008-08-29 2010-03-04 Genentech, Inc. Diagnostics et traitements de tumeurs indépendantes du vegf
WO2010027981A1 (fr) * 2008-09-03 2010-03-11 Genentech, Inc. Anticorps multispécifiques
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
SG10201605250SA (en) 2008-10-14 2016-08-30 Genentech Inc Immunoglobulin variants and uses thereof
KR20170015525A (ko) 2008-11-22 2017-02-08 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
US20100143290A1 (en) * 2008-12-04 2010-06-10 Lallatin Nathaniel C Monoclonal antibodies to human thymidine kinase to treat cancer
WO2010075420A1 (fr) 2008-12-23 2010-07-01 Genentech, Inc. Procédés et compositions pour une utilisation diagnostique chez les patients atteints de cancer
EP2386062B1 (fr) * 2009-01-09 2016-01-06 Oxford Biomedica (UK) Ltd Facteurs
CN102333544A (zh) 2009-02-06 2012-01-25 通用医疗公司 治疗血管损伤的方法
MA33198B1 (fr) 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
CN102369215B (zh) 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
DK2417156T3 (en) 2009-04-07 2015-03-02 Roche Glycart Ag Trivalent, bispecific antibodies
SG175289A1 (en) * 2009-04-20 2011-11-28 Genentech Inc Adjuvant cancer therapy
JP6059013B2 (ja) 2009-05-08 2017-01-11 バクシネックス インコーポレーティッド 抗ｃｄ１００抗体およびこれを使用するための方法
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
BRPI1012321A8 (pt) * 2009-06-17 2016-09-27 Abbott Biotherapeutics Corp Anticorpos anti-vegf e seus usos
KR20120106935A (ko) 2009-07-13 2012-09-27 제넨테크, 인크. 암의 치료를 위한 진단 방법 및 조성물
AR077595A1 (es) 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
AU2010278844A1 (en) * 2009-07-31 2012-02-09 Genentech, Inc. Inhibition of tumor metastasis using Bv8- or G-CSF-antagonists
TW201431558A (zh) * 2009-08-15 2014-08-16 建南德克公司 用於治療先前治療過之乳癌之抗-血管新生療法
US20180057602A1 (en) * 2009-08-17 2018-03-01 Tracon Pharmaceuticals, Inc. Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
EP3281637A1 (fr) * 2009-08-17 2018-02-14 Tracon Pharmaceuticals, Inc. Polythérapie du cancer au moyen d anticorps anti-endogline et d agents anti-vegf
WO2011028642A1 (fr) 2009-09-04 2011-03-10 University Of Louisville Research Foundation, Inc. Déterminants génétiques d'un risque de cancer de la prostate
JP2013504595A (ja) 2009-09-11 2013-02-07 ジェネンテック， インコーポレイテッド 抗癌剤に対する応答の可能性が増加した患者を同定するための方法
JP6091894B2 (ja) 2009-09-16 2017-03-15 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
KR101557545B1 (ko) 2009-09-17 2015-10-06 에프. 호프만-라 로슈 아게 암 환자에서 진단 용도를 위한 방법 및 조성물
WO2011056502A1 (fr) 2009-10-26 2011-05-12 Genentech, Inc. Compositions du gene recepteur de proteine morphogenetique osseuse type ii et procedes d'utilisation
WO2011056497A1 (fr) 2009-10-26 2011-05-12 Genentech, Inc. Compositions de récepteur de l'activine de type iib et leurs méthodes d'utilisation
EP2493458A2 (fr) * 2009-10-30 2012-09-05 The Ohio State University Particules biodégradables multifonctionnelles permettant un ciblage sélectionnable, une imagerie, et une administration thérapeutique, et leur utilisation pour le traitement de troubles oculaires
EP3168232B1 (fr) 2009-11-13 2021-09-29 Dana-Farber Cancer Institute, Inc. Compositions, kits et procédés de diagnostic, pronostic, suivi, traitement et modulation des troubles lymphoprolifératif post-transplantation et troubles de l'angiogenèse associés à l'hypoxie utilisant de la galectine-1
US8486397B2 (en) 2009-12-11 2013-07-16 Genentech, Inc. Anti-VEGF-C antibodies and methods using same
PL2515941T3 (pl) 2009-12-21 2020-04-30 F. Hoffmann-La Roche Ag Preparat farmaceutyczny zawierający bewacyzumab
US8771685B2 (en) 2009-12-23 2014-07-08 F. Hoffmann-La Roche Ag Anti-BV8 antibodies and uses thereof
MX2012009554A (es) * 2010-02-23 2012-11-23 Hoffmann La Roche Terapia anti-angiogenesis para el tratamiento del cancer ovarico.
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
ES2600912T3 (es) 2010-03-29 2017-02-13 Abraxis Bioscience, Llc Métodos para tratar el cáncer
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
WO2011153243A2 (fr) 2010-06-02 2011-12-08 Genentech, Inc. Thérapie anti-angiogénique utilisée dans le traitement du cancer de l'estomac
WO2011153224A2 (fr) 2010-06-02 2011-12-08 Genentech, Inc. Procédés diagnostiques et compositions de traitement du cancer
WO2011153010A1 (fr) 2010-06-04 2011-12-08 Abraxis Biosciences, Llc Procédés de traitement du cancer du pancréas
KR20130126576A (ko) 2010-07-19 2013-11-20 에프. 호프만-라 로슈 아게 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
JP2013537522A (ja) 2010-07-19 2013-10-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗癌治療への応答可能性の増大した患者を同定する方法
US20130177500A1 (en) 2010-07-23 2013-07-11 Trustee Of Boston University Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
WO2012025530A1 (fr) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Anticorps bispécifiques comprenant un fragment fv stabilisé par bisulfure
NZ610487A (en) 2010-11-15 2015-03-27 Five Prime Therapeutics Inc Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
TWI807362B (zh) 2010-11-30 2023-07-01 日商中外製藥股份有限公司 細胞傷害誘導治療劑
EP2655413B1 (fr) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Complexe polypeptide-polynucléotide et son utilisation dans l'administration d'une fraction effectrice ciblée
CN103649117B (zh) 2011-02-04 2016-09-14 霍夫曼-拉罗奇有限公司 Fc变体及其生成方法
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
BR112013019975A2 (pt) 2011-02-28 2017-08-01 Hoffmann La Roche proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
SG10201504303SA (en) 2011-04-01 2015-07-30 Genentech Inc Combinations Of AKT Inhibitor Compounds And Chemotherapeutic Agents, And Methods Of Use
CN103781798B (zh) 2011-04-20 2018-03-13 阿塞勒隆制药公司 内皮糖蛋白多肽及其用途
CA2834776A1 (fr) 2011-05-03 2012-11-08 Genentech, Inc. Agents d'interruption vasculaire et utilisations associees
US10260097B2 (en) * 2011-06-02 2019-04-16 Almac Diagnostics Limited Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
WO2012167122A1 (fr) 2011-06-03 2012-12-06 Indiana University Research And Technology Corporation Composés, compositions et méthodes de traitement de troubles de dommage oxydant de l'adn
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
RU2014109985A (ru) 2011-08-17 2015-09-27 Дженентек, Инк. Ингибирование ангиогенеза в рефрактерных опухолях
MX357391B (es) 2011-09-30 2018-07-06 Regeneron Pharma Anticuerpos anti-erbb3 y usos de los mismos.
KR101999872B1 (ko) 2011-10-11 2019-07-12 백시넥스 인코포레이티드 혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도
US10350188B2 (en) * 2011-11-04 2019-07-16 Myron R. Szewczuk Use of Neu1 sialidase inhibitors in the treatment of cancer
BR112014012005A2 (pt) 2011-11-21 2017-12-19 Genentech Inc composições, métodos, formulação farmacêutica e artigo
WO2013082511A1 (fr) 2011-12-02 2013-06-06 Genentech, Inc. Procédés pour surmonter la résistance tumorale aux antagonistes de vegf
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
FR2984750B1 (fr) * 2011-12-23 2014-01-10 Lfb Biotechnologies Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
JP6486686B2 (ja) 2012-02-10 2019-03-20 ジェネンテック， インコーポレイテッド 単鎖抗体及び他のヘテロ多量体
MX365139B (es) 2012-03-13 2019-05-24 Hoffmann La Roche Uso de una terapia combinada de bevacizumab y paclitaxel en el tratamiento de cáncer de ovario epitelial resistente al platino, carcinoma de las trompas de falopio resistente al platino, o carcinoma peritoneal primario resistente al platino.
CN111420032A (zh) * 2012-03-29 2020-07-17 阿尔托生物科学有限公司 用于治疗肿瘤的方法
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
CN103417965B (zh) * 2012-05-17 2018-04-13 江苏先声药业有限公司 一种含有抗vegf抗体的药物组合物
SG11201407512VA (en) 2012-05-18 2014-12-30 Genentech Inc High-concentration monoclonal antibody formulations
EP2855528B1 (fr) * 2012-05-31 2019-06-19 Genentech, Inc. Procédés de traitement du cancer au moyen d'antagonistes liant l'axe pd-1 et d'antagonistes de vegf
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
MX2014014804A (es) 2012-06-27 2015-02-12 Hoffmann La Roche Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
CN104395339A (zh) 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
EP3603664A1 (fr) 2012-07-05 2020-02-05 Vaximm AG Vaccin à adn, destiné à être utilisé chez des patients atteints de cancer du pancréas
MX361337B (es) 2012-07-13 2018-12-04 Roche Glycart Ag Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares.
CN104507498A (zh) 2012-08-07 2015-04-08 霍夫曼-拉罗奇有限公司 用于治疗成胶质细胞瘤的组合疗法
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US9877981B2 (en) 2012-10-09 2018-01-30 President And Fellows Of Harvard College NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
AU2013353839A1 (en) 2012-12-03 2015-06-18 Almac Diagnostics Limited Molecular diagnostic test for cancer
US9770426B2 (en) 2013-01-11 2017-09-26 Massachusetts Eye And Ear Infirmary CYP450 lipid metabolites reduce inflammation and angiogenesis
US9500464B2 (en) * 2013-03-12 2016-11-22 Adidas Ag Methods of determining performance information for individuals and sports objects
WO2014160490A1 (fr) 2013-03-13 2014-10-02 Genetech, Inc. Formulations d'anticorps
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
GB2516561B (en) * 2013-03-15 2016-03-09 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
PT3611180T (pt) 2013-03-15 2022-03-15 Biomolecular Holdings Llc Imunoglobulina híbrida que contém uma ligação não peptídica
CN105307669A (zh) 2013-05-23 2016-02-03 戊瑞治疗有限公司 治疗癌症的方法
KR101541478B1 (ko) * 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
WO2014209802A1 (fr) 2013-06-25 2014-12-31 Vaccinex, Inc. Utilisation de molécules d'inhibition de sémaphorine-4d en combinaison avec une thérapie de modulation immunitaire pour inhiber la croissance tumorale et les métastases
CN104341504B (zh) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
JP6422956B2 (ja) 2013-10-11 2018-11-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性ドメイン交換共通可変軽鎖抗体
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
EA035481B1 (ru) 2013-10-25 2020-06-23 Акселерон Фарма, Инк. Эндоглиновые пептиды для лечения фиброзных заболеваний
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
EP3660050A1 (fr) 2014-03-14 2020-06-03 Novartis AG Molécules d'anticorps anti-lag-3 et leurs utilisations
NZ724904A (en) 2014-03-14 2023-04-28 Biomolecular Holdings Llc Hybrid immunoglobulin containing non-peptidyl linkage
EP3122900A1 (fr) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
MX2016012779A (es) 2014-03-31 2017-04-27 Genentech Inc Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
KR20230164192A (ko) 2014-05-06 2023-12-01 제넨테크, 인크. 포유동물 세포를 사용한 이종다량체 단백질의 생산
JP2017523776A (ja) 2014-07-14 2017-08-24 ジェネンテック， インコーポレイテッド 膠芽腫の診断方法及びその治療用組成物
EP3180018B1 (fr) 2014-08-12 2019-07-24 Massachusetts Institute Of Technology Traitement tumoral synergique avec il-2 une protéine de fusion de fc liant l'intégrine
US20170224777A1 (en) 2014-08-12 2017-08-10 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
EA035979B1 (ru) 2014-09-09 2020-09-08 Янссен Байотек, Инк. Варианты комбинированной терапии анти-cd38 антителами
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
US20160137727A1 (en) 2014-09-15 2016-05-19 Genentech, Inc. Antibody formulations
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US20170209574A1 (en) 2014-10-03 2017-07-27 Novartis Ag Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
CA2960297A1 (fr) 2014-11-10 2016-05-19 Genentech, Inc. Anticorps anti-interleukine 33 et leurs utilisations
PL3227332T3 (pl) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
KR102597989B1 (ko) 2014-12-04 2023-11-02 얀센 바이오테크 인코포레이티드 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
EP3237639A2 (fr) 2014-12-23 2017-11-01 Genentech, Inc. Compositions et méthodes destinées à traiter et à diagnostiquer des cancers résistant à la chimiothérapie
ES2651442T3 (es) * 2014-12-30 2018-01-26 Curadis Gmbh Esteroides C-19 para inhibir la neovascularización
WO2016159213A1 (fr) 2015-04-01 2016-10-06 中外製薬株式会社 Procédé pour la production d'un hétéro-oligomère polypeptidique
EP3286227A2 (fr) 2015-04-24 2018-02-28 F. Hoffmann-La Roche AG Protéines multispécifiques de liaison à l'antigène
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
IL319936A (en) 2015-05-20 2025-05-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
KR20180025888A (ko) 2015-06-08 2018-03-09 제넨테크, 인크. 항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
WO2016209921A1 (fr) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Polythérapies pour malignités hématologiques avec des anticorps anti-cd38 et des inhibiteurs de la survivine
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
PL3317301T3 (pl) 2015-07-29 2021-11-15 Novartis Ag Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
EP3316902A1 (fr) 2015-07-29 2018-05-09 Novartis AG Polythérapies comprenant des molécules d'anticorps contre tim -3
WO2017031442A1 (fr) 2015-08-20 2017-02-23 Merrimack Pharmaceuticals, Inc. Traitement combiné utilisant l'irinotécan liposomal et un inhibiteur de parp pour un traitement anticancéreux
JP2018528185A (ja) 2015-08-21 2018-09-27 イプセン バイオファーム リミティド リポソーム型イリノテカン及びオキサリプラチンを含む組み合わせ療法を使用して転移性膵臓癌を治療するための方法
EP3349796A4 (fr) 2015-09-17 2019-05-29 ImmunoGen, Inc. Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1
CN116987187A (zh) 2015-09-23 2023-11-03 豪夫迈·罗氏有限公司 抗-vegf抗体的优化的变体
ES2870141T3 (es) 2015-10-30 2021-10-26 Hoffmann La Roche Anticuerpos anti-HtrA1 y procedimientos de uso de los mismos
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
EP4516319A3 (fr) 2015-11-03 2025-05-07 Janssen Biotech, Inc. Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
MY198562A (en) 2015-11-03 2023-09-05 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
BR112018068363A2 (pt) * 2016-03-14 2019-01-15 Chugai Seiyaku Kabushiki Kaisha fármaco terapêutico indutor de dano celular para uso em terapia de câncer
WO2017165681A1 (fr) 2016-03-24 2017-09-28 Gensun Biopharma Inc. Inhibiteurs trispécifiques pour le traitement du cancer
KR20190003958A (ko) 2016-04-15 2019-01-10 제넨테크, 인크. 암의 치료 및 모니터링 방법
JP2019515670A (ja) 2016-04-15 2019-06-13 ジェネンテック， インコーポレイテッド がんをモニタリングし治療するための方法
EP3482205A1 (fr) 2016-07-08 2019-05-15 H. Hoffnabb-La Roche Ag Utilisation de la protéine 4 d'épididyme humaine (he4) pour évaluer la sensibilité à un traitement d'un cancer positif pour muc16
CN109890982B (zh) 2016-07-08 2023-07-07 基因泰克公司 通过nrf2及其下游目标基因的表达状态和突变状态诊断和治疗癌症的方法
EP3515494A4 (fr) 2016-09-26 2020-10-07 The Brigham and Women's Hospital, Inc. Régulateurs de l'immunosuppression médiée par lymphocytes b
KR20190077441A (ko) 2016-11-02 2019-07-03 입센 바이오팜 리미티드 리포솜성 이리노테칸, 옥살리플라틴, 5-플루오로우라실 (및 류코보린)을 포함하는 조합 요법을 사용하는 위암 치료
WO2018128939A1 (fr) 2017-01-05 2018-07-12 Gensun Biopharma Inc. Antagonistes de régulateur de point de contrôle
WO2018132516A1 (fr) 2017-01-10 2018-07-19 Nodus Therapeutics Polythérapie pour le traitment de tumeurs avec une protéine de fusion fc de liaison à l'intégrine et un modulateur immunitaire
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
EP3589754B1 (fr) 2017-03-01 2023-06-28 F. Hoffmann-La Roche AG Procédés diagnostiques et thérapeutiques relatifs au cancer
EP3642240A1 (fr) 2017-06-22 2020-04-29 Novartis AG Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
KR20200021087A (ko) 2017-06-22 2020-02-27 노파르티스 아게 Cd73에 대한 항체 분자 및 이의 용도
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
PE20210844A1 (es) 2017-11-01 2021-05-10 Hoffmann La Roche Contorsbodies 2 + biespecificos
WO2019129677A1 (fr) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Anticorps anti-vegf et procédés d'utilisation
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
CN111989095A (zh) 2018-04-16 2020-11-24 上海岸阔医药科技有限公司 预防或治疗肿瘤疗法副作用的方法
CN112739716B (zh) 2018-05-07 2025-05-27 展马博联合股份有限公司 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法
MA52777A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Agents de liaison psma et utilisations correspondantes
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (fr) 2018-05-31 2019-12-05 Novartis Ag Molécules d'anticorps anti-cd73 et leurs utilisations
US11001635B2 (en) 2018-06-29 2021-05-11 Gensun Biopharma Inc. Antitumor antagonists
KR20210079311A (ko) 2018-10-18 2021-06-29 제넨테크, 인크. 육종성 신장암에 대한 진단과 치료 방법
TWI844571B (zh) * 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
AR118720A1 (es) 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
WO2020226986A2 (fr) 2019-05-03 2020-11-12 Genentech, Inc. Méthodes de traitement de cancer au moyen d'un anticorps anti-pd-l1
CN112010971A (zh) * 2019-05-30 2020-12-01 义慧科技(深圳)有限公司 抗vegf抗体在制备预防和/或治疗脂肪肝的药物中的应用
EP3990116A1 (fr) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTAGONISTE ANTITUMORAL COMPOSÉ D'UN DOMAINE EXTRACELLULAIRE TGFß1 - RII MUTÉ ET D'UN ÉCHAFAUDAGE D'IMMUNOGLOBULINE
WO2021013080A1 (fr) 2019-07-19 2021-01-28 神州细胞工程有限公司 Anticorps monoclonal anti-vegf humanisé
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
PH12022552371A1 (en) 2020-03-13 2023-12-18 Genentech Inc Anti-interleukin-33 antibodies and uses thereof
CA3172449A1 (fr) 2020-03-27 2021-09-30 Erik Hans MANTING Utilisation ex vivo de cellules modifiees d'origine leucemique pour ameliorer l'efficacite d'une therapie cellulaire adoptive
EP4127724A1 (fr) 2020-04-03 2023-02-08 Genentech, Inc. Procédés thérapeutiques et de diagnostic du cancer
CN116133679A (zh) 2020-06-30 2023-05-16 门德斯有限公司 白血病衍生细胞在卵巢癌疫苗中的用途
EP4225377A4 (fr) * 2020-10-12 2024-11-27 Medicenna Therapeutics, Inc. Polythérapie de mdna55 et d'un facteur de croissance vasculaire endothéliale a (vegf-a)
AU2021377810B2 (en) 2020-11-13 2025-01-02 Genentech, Inc. Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors
CA3203705A1 (fr) 2021-01-22 2022-07-28 Erik Hans MANTING Procedes de vaccination antitumorale
PE20240761A1 (es) 2021-01-28 2024-04-17 Janssen Biotech Inc Proteinas de union a psma y usos de estas
WO2022190058A1 (fr) 2021-03-12 2022-09-15 Dcprime B.V. Méthodes de vaccination et utilisation d'un blocage de cd47
KR20220141572A (ko) 2021-04-13 2022-10-20 김문재 확장형 실내 캠핑실이 삽입 및 인출되는 차량
WO2022232503A1 (fr) 2021-04-30 2022-11-03 Genentech, Inc. Méthodes thérapeutiques et diagnostiques et compositions contre le cancer
WO2022256820A1 (fr) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Antagonistes multispécifiques
CN120695174A (zh) * 2021-07-01 2025-09-26 江苏先声生物制药有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
KR20240028452A (ko) 2021-07-02 2024-03-05 제넨테크, 인크. 암을 치료하기 위한 방법 및 조성물
AU2022317820A1 (en) 2021-07-28 2023-12-14 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
WO2023080900A1 (fr) 2021-11-05 2023-05-11 Genentech, Inc. Procédés et compositions pour classer et traiter le cancer rénal
WO2023144973A1 (fr) 2022-01-27 2023-08-03 中外製薬株式会社 Composition pharmaceutique contenant un anticorps anti-pd-l1, à utiliser en combinaison avec un anticorps anti-vegf et du paclitaxel
US20250170090A1 (en) 2022-01-28 2025-05-29 Onquality Pharmaceuticals China Ltd. Method for preventing or treating disease or disorder associated with antineoplastic agent
KR20240150493A (ko) 2022-02-21 2024-10-15 온퀄리티 파마슈티컬스 차이나 리미티드 화합물 및 그 용도
WO2024263195A1 (fr) 2023-06-23 2024-12-26 Genentech, Inc. Méthodes de traitement du cancer du foie
WO2024263904A1 (fr) 2023-06-23 2024-12-26 Genentech, Inc. Méthodes de traitement du cancer du foie

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (fr) 1979-10-18 1981-04-30 Univ Illinois Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987005330A1 (fr) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Procede pour ameliorer la stabilite des glycoproteines
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5036003A (en) 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2095633C (fr) 1990-12-03 2003-02-04 Lisa J. Garrard Methode d'enrichissement de proteines variantes aux proprietes liantes alterees
EP0536350B1 (fr) 1991-02-22 2002-08-07 American Cyanamid Company Identification d'un nouveau gene humain recepteur de tyrosine kinase
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20020032313A1 (en) * 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
OA10149A (en) * 1991-03-29 1996-12-18 Genentech Inc Vascular endothelial cell growth factor antagonists
US20010021382A1 (en) 1991-03-29 2001-09-13 Genentech, Inc. Vascular endothelial cell growth factor antagonists
EP0586505A1 (fr) 1991-05-14 1994-03-16 Repligen Corporation Anticorps d'heteroconjugues pour le traitement des infections a l'hiv
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
EP0617706B1 (fr) 1991-11-25 2001-10-17 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
JPH08500017A (ja) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド 二特異的免疫アドヘジン
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20060193862A1 (en) * 1995-03-30 2006-08-31 Genentech, Inc. Vascular endothelial cell growth factor antagonists
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
SI1516628T1 (sl) 1995-07-27 2013-10-30 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
JPH10114680A (ja) 1996-10-08 1998-05-06 Toagosei Co Ltd 制癌剤
US20150023951A1 (en) 1997-04-07 2015-01-22 Genentech, Inc. Anti-vegf antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US20070059302A1 (en) * 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
WO1998045331A2 (fr) * 1997-04-07 1998-10-15 Genentech, Inc. Anticorps anti-vegf
SI1695985T1 (sl) 1997-04-07 2011-06-30 Genentech Inc Postopki za tvorbo humaniziranih protiteles z naključno mutagenezo
ATE516354T1 (de) 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
ATE517125T1 (de) 1998-01-26 2011-08-15 Genentech Inc ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN
DE69926536T3 (de) * 1998-12-22 2013-09-12 Genentech, Inc. Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
DK1140198T3 (da) 1999-01-13 2008-03-10 Alchemia Oncology Pty Ltd Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
WO2000064946A2 (fr) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions et procedes de traitement du cancer par inhibition selective de vegf
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
RU2177349C1 (ru) 2001-02-20 2001-12-27 Центральный научно-исследовательский рентгено-радиологический институт МЗ РФ Способ лечения инфильтративно-отечного рака молочной железы
JP2005525368A (ja) 2002-03-04 2005-08-25 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストをＨＭＧ−ＣｏＡ還元酵素阻害剤またはビスフォスフォネートと併用投与する障害の予防または治療方法
CN1187373C (zh) 2002-03-20 2005-02-02 上海中信国健药业有限公司 人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物
US20070036755A1 (en) * 2004-05-28 2007-02-15 Genentech, Inc. Treatment with anti-vegf antibodies
RS20050885A (sr) * 2003-05-30 2008-04-04 Genentech Lečenje sa anti-vegf antitelima
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2

Also Published As

Publication number Publication date
KR20180132969A (ko) 2018-12-12
IL246594A0 (en) 2016-08-31
US20070036754A1 (en) 2007-02-15
US20070160608A1 (en) 2007-07-12
KR20170073698A (ko) 2017-06-28
US20070071749A1 (en) 2007-03-29
US20080248036A1 (en) 2008-10-09
KR20150008458A (ko) 2015-01-22
WO2005000900A1 (fr) 2005-01-06
RS20050885A (sr) 2008-04-04
EP2311875A1 (fr) 2011-04-20
US20130195847A1 (en) 2013-08-01
US20160304594A1 (en) 2016-10-20
KR20160114727A (ko) 2016-10-05
US20080166351A1 (en) 2008-07-10
US20080292630A1 (en) 2008-11-27
MXPA05012723A (es) 2006-02-08
US20070036790A1 (en) 2007-02-15
JP2011144188A (ja) 2011-07-28
US20180221473A1 (en) 2018-08-09
US20200171148A1 (en) 2020-06-04
NZ621449A (en) 2015-07-31
JP2020121984A (ja) 2020-08-13
US20080241148A1 (en) 2008-10-02
US20070258984A1 (en) 2007-11-08
US20150359881A1 (en) 2015-12-17
RU2009149451A (ru) 2011-07-10
US20070148177A1 (en) 2007-06-28
ME00425B (me) 2011-10-10
JP2018012705A (ja) 2018-01-25
CR8108A (es) 2007-06-20
KR20200034817A (ko) 2020-03-31
JP2016074681A (ja) 2016-05-12
CN101274098A (zh) 2008-10-01
RS20150135A1 (sr) 2015-08-31
US7622115B2 (en) 2009-11-24
RS20160203A1 (sr) 2016-10-31
AU2008243227A1 (en) 2008-12-04
US20070036753A1 (en) 2007-02-15
US20140178369A1 (en) 2014-06-26
RU2014109776A (ru) 2015-09-20
US20210015918A1 (en) 2021-01-21
US20070031413A1 (en) 2007-02-08
US20070071748A1 (en) 2007-03-29
JP2007525466A (ja) 2007-09-06
EP2248829A1 (fr) 2010-11-10
CO5640150A2 (es) 2006-05-31
US20080160029A1 (en) 2008-07-03
US9795672B2 (en) 2017-10-24
EP1629010A1 (fr) 2006-03-01
US20100226880A1 (en) 2010-09-09
US20070025999A1 (en) 2007-02-01
IL171833A (en) 2014-12-31
US20130028862A1 (en) 2013-01-31
KR20160014775A (ko) 2016-02-11
NO20056236L (no) 2006-02-28
IL232718A0 (en) 2014-07-31
KR20110118738A (ko) 2011-10-31
JP2019055965A (ja) 2019-04-11
US20190307881A1 (en) 2019-10-10
US20070148178A1 (en) 2007-06-28
JP2007326860A (ja) 2007-12-20
RU2017109912A (ru) 2019-01-23
EP2251355A1 (fr) 2010-11-17
US20070154483A1 (en) 2007-07-05
BRPI0411200A (pt) 2006-07-18
US20080267968A1 (en) 2008-10-30
US20090246173A1 (en) 2009-10-01
KR20120104408A (ko) 2012-09-20
IL235814A0 (en) 2014-12-31
UA101945C2 (uk) 2013-05-27
US20080248049A1 (en) 2008-10-09
CA2526085A1 (fr) 2005-01-06
RS20181002A1 (sr) 2018-12-31
TNSN05300A1 (en) 2007-07-10
US20080279860A1 (en) 2008-11-13
US20230218755A1 (en) 2023-07-13
US20090010883A1 (en) 2009-01-08
ECSP056187A (es) 2006-04-19
US20050186208A1 (en) 2005-08-25
US20090053216A1 (en) 2009-02-26
KR20190085166A (ko) 2019-07-17
US20090010881A1 (en) 2009-01-08
RU2017109912A3 (fr) 2020-05-28
KR20180014881A (ko) 2018-02-09
JP2013224301A (ja) 2013-10-31
RU2519669C2 (ru) 2014-06-20
US20070071718A1 (en) 2007-03-29
AU2004251168A1 (en) 2005-01-06
KR20060006975A (ko) 2006-01-20
ZA200509059B (en) 2007-01-31
US20110123494A1 (en) 2011-05-26
RS20170595A1 (sr) 2017-09-29
RU2005136988A (ru) 2006-06-10
US20080292631A1 (en) 2008-11-27
CN1829741A (zh) 2006-09-06
US20160310592A1 (en) 2016-10-27
US20090191215A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
MA27854A1 (fr) Traitement au moyen d'anticorps anti-vegf
EA200100939A1 (ru) Продолжительно действующие инсулинотропные пептиды
HUP0301877A2 (hu) Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek
CY1110721T1 (el) Χρηση glp-2 σε συνδυασμο με αλλο θεραπευτικο παραγοντα σε οστικες παθησεις
FR13C0068I2 (fr) Conjugues du maytansinoide dm1 avec l'anticorps trastuzumab, attache par une liaison non-clivable, et son utilisation dans le traitement des tumeurs.
EA200300628A1 (ru) Соединения, специфические к аденозиновому a, aи aрецептору, и их применение
FR2869231A1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
ATE554763T1 (de) Photodynamische therapie der mit der altersbezogenen makuladegeneration verbundenen okkulten chorioidalen neovaskularisation
CY1118429T1 (el) Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
NZ595262A (en) Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease
WO2003096990A3 (fr) Cages proteiques pour l'administration d'agents therapeutiques et d'imagerie medicale
DE60128216D1 (de) Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen
MA28149A1 (fr) Compositions de vaccin comprenant une interleukine 18 et un systeme adjuvant de type saponine
NO20044462L (no) Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer
EP2081435A4 (fr) Inhibiteurs de la tyrosine kinase de bruton
DE60022021D1 (de) Zubereitungen enthaltend Apomorphin und Sildenafil und ihre Verwendung zur Behandlung von erektiler Dysfunktion
MEP42808A (en) Use of flibanserin in the treatment of sexual disorders
BR0206160A (pt) Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos
EP1467757A4 (fr) Utilisation d'anticorps diriges contre l'antigene muc18
CY1111999T1 (el) Λακτοφερρινη στην αγωγη κακοηθων νεοπλασματων και αλλων υπερπλαστικων νοσων
EA200501690A1 (ru) Композиция, включающая ингибитор pde4 и ингибитор pde5
EA200700427A1 (ru) Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
MA32566B1 (fr) Anticorps neutralisant les cytomégalovirus humains et leurs utilisations
WO2003103585A3 (fr) Methodes de traitement de l'angiogenese, de la croissance tumorale et de metastases
ATE355288T1 (de) Verbindungen und therapeutische methoden